Ashish Sharma1, Keerthi Bellala2,3, Pankaj Dongre2,3, Prahalad Reddy2. 1. Department of Vitreoretina, Lotus Eye Hospital, and Institute, Avinashi Road, Coimbatore, TN, 641014, India. drashish79@hotmail.com. 2. Department of Vitreoretina, Lotus Eye Hospital, and Institute, Avinashi Road, Coimbatore, TN, 641014, India. 3. Department of Retina and Vitreous Surgery, L V Prasad Eye Institute, GMRV Campus, Visakhapatnam, Andhra Pradesh, India.
Abstract
PURPOSE: To compare the efficacy and safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection versus dexamethasone implant (Ozurdex) for the treatment of center-involved DME (CiDME). METHOD: This prospective randomized comparative study included 40 eyes (38 patients) of CiDME. They were randomized into two groups. Patients in group A received the intravitreal anti-VEGF injection (bevacizumab 1.25 mg or ranibizumab 0.5 mg) and those in group B received dexamethasone implant (0.7 mg) pro-re-nata after 4 weeks and 3 months, respectively. The primary outcome was measured at 3 months from the baseline that included improvement in BCVA, reduction in CFT, and adverse effects during the follow-up period. RESULTS:Mean best-corrected visual acuity (BCVA) improved from 0.51 ± 0.275 LogMAR units (20/63) to 0.20 ± 0.185 LogMAR units (20/32) in group A and from 0.56 ± 0.213 LogMAR units (20/80) to 0.141 ± 0.177 LogMAR units (20/32) in group B at 3 months. There was no significant difference in mean BCVA between both the groups (p = .27). The mean central foveal thickness (CFT) improved from 443.55 ± 131.536 µ to 277.66 ± 76.184 µ and from 460.95 ± 125.462 µ to 233.25 ± 37.552 µ at 3 months in group B (p = .02). CONCLUSION: Both the groups had the similar visual outcome. However, the superior anatomical result was observed in dexamethasone implant group during this short follow-up.
RCT Entities:
PURPOSE: To compare the efficacy and safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection versus dexamethasone implant (Ozurdex) for the treatment of center-involved DME (CiDME). METHOD: This prospective randomized comparative study included 40 eyes (38 patients) of CiDME. They were randomized into two groups. Patients in group A received the intravitreal anti-VEGF injection (bevacizumab 1.25 mg or ranibizumab 0.5 mg) and those in group B received dexamethasone implant (0.7 mg) pro-re-nata after 4 weeks and 3 months, respectively. The primary outcome was measured at 3 months from the baseline that included improvement in BCVA, reduction in CFT, and adverse effects during the follow-up period. RESULTS: Mean best-corrected visual acuity (BCVA) improved from 0.51 ± 0.275 LogMAR units (20/63) to 0.20 ± 0.185 LogMAR units (20/32) in group A and from 0.56 ± 0.213 LogMAR units (20/80) to 0.141 ± 0.177 LogMAR units (20/32) in group B at 3 months. There was no significant difference in mean BCVA between both the groups (p = .27). The mean central foveal thickness (CFT) improved from 443.55 ± 131.536 µ to 277.66 ± 76.184 µ and from 460.95 ± 125.462 µ to 233.25 ± 37.552 µ at 3 months in group B (p = .02). CONCLUSION: Both the groups had the similar visual outcome. However, the superior anatomical result was observed in dexamethasone implant group during this short follow-up.
Entities:
Keywords:
Anti-VEGF; Centre involved diabetic macular edema (CiDME); Ozurdex implant
Authors: Careen Lowder; Rubens Belfort; Sue Lightman; C Stephen Foster; Michael R Robinson; Rhett M Schiffman; Xiao-Yan Li; Harry Cui; Scott M Whitcup Journal: Arch Ophthalmol Date: 2011-01-10
Authors: David J Browning; Adam R Glassman; Lloyd Paul Aiello; Roy W Beck; David M Brown; Donald S Fong; Neil M Bressler; Ronald P Danis; James L Kinyoun; Quan Dong Nguyen; Abdhish R Bhavsar; Justin Gottlieb; Dante J Pieramici; Michael E Rauser; Rajendra S Apte; Jennifer I Lim; Päivi H Miskala Journal: Ophthalmology Date: 2006-11-21 Impact factor: 12.079
Authors: Ranjan Rajendram; Samantha Fraser-Bell; Andrew Kaines; Michel Michaelides; Robin D Hamilton; Simona Degli Esposti; Tunde Peto; Catherine Egan; Catey Bunce; Richard David Leslie; Philip G Hykin Journal: Arch Ophthalmol Date: 2012-08
Authors: Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf Journal: Diabetes Care Date: 2010-11 Impact factor: 19.112
Authors: Christine Aroney; Samantha Fraser-Bell; Ecosse L Lamoureux; Mark C Gillies; Lyndell L Lim; Eva K Fenwick Journal: Invest Ophthalmol Vis Sci Date: 2016-10-01 Impact factor: 4.799
Authors: Hemal Mehta; Samantha Fraser-Bell; Aaron Yeung; Anna Campain; Lyndell L Lim; Godfrey J Quin; Ian L McAllister; Pearse A Keane; Mark C Gillies Journal: Br J Ophthalmol Date: 2015-11-04 Impact factor: 4.638